Tag: Xanomeline trospium

In September 2024, the FDA approved xanomeline-trospium (Cobenfy) for the treatment of schizophrenia, representing the first new class of antipsychotic medication to market in decades that does not primarily target dopamine receptors. Understanding **how does xanomeline affect the brain?** requires exploring its innovative mechanism centered on the brain's cholinergic system, a fundamental pathway for cognition and behavior.

Clozapine is widely considered the most effective treatment for treatment-resistant schizophrenia, despite its severe side effect profile and intensive monitoring requirements. With the recent FDA approval of Cobenfy in 2024, a new paradigm for treating schizophrenia has emerged, raising the critical question: is Cobenfy better than clozapine?.

For decades, negative symptoms in schizophrenia have been notoriously difficult to treat, with traditional antipsychotics primarily targeting positive symptoms. A major development in this field is the FDA approval of Cobenfy (KarXT) in 2024, raising the question: what is the new antipsychotic for negative symptoms and how does it work differently?.

Affecting about 1% of the population, schizophrenia has been treated largely with dopamine-targeting medications for decades. The recent FDA approval of **COBENFY**, a new schizophrenia drug, marks a significant shift with its novel, non-dopamine mechanism of action. This first-in-class muscarinic agonist represents a new pharmacological approach to managing schizophrenia symptoms in adults.